Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00770367 · ClinicalTrials.gov registry record · Phase 4
Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes
A Phase 4 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT00770367 is a Phase 4 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 36 participants.
The verdict
NCT00770367, a Phase 4 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
SPECIFIC AIMS 1. To determine whether pioglitazone will reduce levels of asymmetric dimethylarginine(ADMA) in patients with diabetes. 2. To determine whether nitric oxide(NOx) products are increased with pioglitazone treatment. 3. To determine whether pioglitazone reduces oxidative stress (F2-isoprostanes).
Interventions
- DRUG Pioglitazone then Placebo
- DRUG Placebo then Pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00770367
The ClinicalTrials.gov registry entry for NCT00770367 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pioglitazone then Placebo is the first listed.
NCT00770367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00770367 about?
NCT00770367 is a clinical study titled "Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes". SPECIFIC AIMS 1. To determine whether pioglitazone will reduce levels of asymmetric dimethylarginine(ADMA) in patients with diabetes. 2. To determine whether nitric oxide(NOx) products are increased with pioglitazone treatment. 3. To determine whether pioglitazone reduces oxidative stress (F2-isopr...
What is the current status of trial NCT00770367?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2008-10. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00770367?
The interventions under investigation include: Pioglitazone then Placebo (DRUG), Placebo then Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00770367?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.